The present invention provides compounds of formula I: ##STR00001##
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

A method of preparing a cannabinoid-containing additive includes preparing an oil mixture by combining a cannabinoid oil and a carrier oil, preparing a water base by combining water and an emulsifier blend, and combining the oil mixture and the water base to form a liquid cannabinoid emulsion. The emulsion may be dried to form a solid. The cannabinoidcontaining additive, either in the liquid or solid form, is combined with a food and beverage product.

A method of preparing a cannabinoid-containing additive includes preparing an oil mixture by combining a cannabinoid oil and a carrier oil, preparing a water base by combining water and an emulsifier blend, and combining the oil mixture and the water base to form a liquid cannabinoid emulsion. The emulsion may be dried to form a solid. The cannabinoidcontaining additive, either in the liquid or solid form, is combined with a food and beverage product.

A P2X.sub.4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome:

##STR00001##

wherein R.sup.1 is hydrogen, a C.sub.1-8 alkyl group, or the like; each R.sup.2 and R.sup.3 is hydrogen, a C.sub.1-8 alkyl group, or the like; each of R.sup.4 and R.sup.5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

A P2X.sub.4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome:

##STR00001##

wherein R.sup.1 is hydrogen, a C.sub.1-8 alkyl group, or the like; each R.sup.2 and R.sup.3 is hydrogen, a C.sub.1-8 alkyl group, or the like; each of R.sup.4 and R.sup.5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R.sup.1a, R.sup.2a, .sup.A1, A.sup.2, A.sup.3, A.sup.4, R.sup.1b, R.sup.2b, B.sup.1, B.sup.2, B.sup.3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R.sup.1a, R.sup.2a, .sup.A1, A.sup.2, A.sup.3, A.sup.4, R.sup.1b, R.sup.2b, B.sup.1, B.sup.2, B.sup.3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

The present disclosure provides methods for treating hematological malignancies using menin inhibitors. Compositions for use in these methods are also provided.

The present disclosure provides methods for treating hematological malignancies using menin inhibitors. Compositions for use in these methods are also provided.